Complix Enters into Strategic Collaboration with MSD to Develop Cell-Penetrating Alphabodies to Treat Cancer

06-01-2016 11:52

Complix Enters into Strategic Collaboration with MSD to Develop Cell-Penetrating Alphabodies to Treat Cancer.
Complix to receive upfront fees, research funding, and milestone payments.

Hasselt, Belgium, January 6 2016 – Complix, a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies™, for the treatment of cancer and severe autoimmune diseases, announced it has entered into a strategic drug discovery collaboration with Merck & Co., Inc. (known as “MSD” or “Merck” (in the United States and Canada)) through its subsidiary, Merck Sharp & Dohme Corp., to develop Cell-Penetrating Alphabodies (CPABs) for the treatment of cancer.

PDF-file 73.3kb

Dutch version - French version - German version